Creative Biolabs is a world-renowned provider of service and products for chimeric antigen receptor (CAR) research. Based on the advanced technologies and rich experience, we have built a broad range of CAR construction service. Above all, the universal CAR construction service is one of the most unique services.
Chimeric antigen receptor (CAR)-based adoptive immunotherapy employs genetically modified T cells to express CARs. Combined specific targeting of antibodies with T cell involved in immune responses, T cells can target the surface of antigens independent. Typically, CARs consist of a single chain antibody fragment (scFv) which are fused to spacer and transmembrane domains. CARs have several advantages over T cell receptors in that CAR is used to treat cancer patients regardless of HLA type. Furthermore, they are resistant to some of the tumor escape mechanisms as malignant cells that have decreased proteasome antigen processing are readily killed.
Although, scFv are prepared to specifically direct against tumor-associated antigens, the recognition specificity potential of CAR-T cells is not enough. Hence, as a leader in CAR-T of research and development, Creative Biolabs has developed a novel strategy of CAR construction named universal CAR to solve this defect. We utilize biotin or anti-fluorescein isothiocyanate (FITC) scFv as targeting region fused with a transmembrane domain and one or two endodomain to construct universal CAR (uCAR). This uCAR expressing T cells can recognize and eliminate cancer cells via binding FITC labeled or biotinylated antigen-specific monocloncal antibodies (mAbs), and the subsequent T cell activation, proliferation, and cytokine production. Moreover, the treatment of immunocompromised mice using the novel uCAR T cells plus the labeled mAbs currently in clinical uses exhibited potent antitumor activity.
After the construction of universal CAR, our scientists can offer you a seriesof services to complete your whole research, including but not limited to CAR cell in vitro assay, CAR preclinical in vivo assay and CAR clinical trials.
With our CAR development platform and advanced technologies, Creative Biolabs has rich experience in universal CAR construction. Our standard pipeline can support rapid and high-quality CAR production. All of our services in this CAR platform can be tailored to meet your special needs. More than that, our services are economical and reliable. If you want to know more about our service, please contact us by E-mail. Our team will be get back to you quickly.
Fig.1 Schematic of Universal Chimeric Antigen Receptors
Huan Shi, et al. Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Molecular Cancer, 2014,13:219.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE